Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

Sartor A. O. , Oudard S., Ozguroglu M., Hansen S., Machiels J. H. , Shen L., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011 (SCI İndekslerine Giren Dergi) identifier